3E Bioventures

Matwings Technology is a biotechnology company that specializes in the design of functionally optimized proteins using advanced evolutionary methods. It focuses on the development of innovative drug molecular design through computational chemistry and artificial intelligence. Matwings collaborates with major pharmaceutical companies to conduct early-stage research and development of drugs targeting complex clinical challenges. The company's goal is to achieve breakthroughs in drug targets that are typically difficult to formulate, emphasizing the clinical value of its innovations.

Rapafusyn Pharmaceuticals is engaged in the development and licensing of innovative pharmaceuticals based on a unique class of natural product-like macrocycles. The company operates a pharmaceutical platform that assists healthcare professionals in generating libraries of hybrid macrocycles using a bifunctional scaffold. This platform allows for the screening of these libraries to identify lead compounds aimed at both novel and validated therapeutic targets. Through its efforts, Rapafusyn Pharmaceuticals seeks to address unmet medical needs and improve treatment options for patients with various diseases.

Arnatar Therapeutics is a biopharmaceutical company that specializes in the development of novel nucleic acid medications.

Tianhu Technology provides drug research and development services through independent collaborative closed-loop iterations, deeply integrating AI solutions with the drug development and production process. Tianhu Technology is an innovative drug R&D company that offers high-throughput phenotypic screening and physical computing technology, as well as AI solutions that are deeply integrated into the drug R&D process.

Varnotech is a biotechnology company founded in 2019 that focuses on the development of vaccines, antibodies, and adjuvants aimed at combating various diseases and viruses. The company is dedicated to creating effective solutions that enhance immune responses, providing innovative human vaccines and adjuvant technologies to improve patient outcomes. Through its research and development efforts, Varnotech strives to address pressing health challenges and contribute to public health initiatives.

Myrobalan Therapeutics is a biotechnology company dedicated to developing oral neurorestorative therapies that target brain dysfunctions and central nervous system (CNS) disorders. The company leverages its deep understanding of neurological processes, including demyelination and neuroinflammation, to identify and develop innovative therapeutic candidates. With a focus on reversing the underlying pathologies of CNS conditions, Myrobalan Therapeutics aims to address significant unmet medical needs. Their dedicated team of scientists employs advanced drug discovery tools to create selective and brain-penetrant therapies, ultimately enabling healthcare professionals to offer new treatment options to a large patient population affected by CNS disorders.

Jushu Biotech is a medical engineering company that focuses on the research and development of synthetic biosensing technology.

Smartlens is a clinical-stage Med Tech company focused on developing innovative technologies for diagnosing and treating glaucoma, a leading cause of irreversible blindness. Its primary product, miLens, is a microfluidic-based smart contact lens designed for continuous monitoring of intraocular pressure (IOP), addressing the urgent need for home-based monitoring solutions. Current clinical trials indicate that miLens offers an accurate alternative to traditional office-based devices, potentially enhancing early diagnosis and personalized treatment for patients. The technology is non-invasive and utilizes a unique electronics-free sensor, which is supported by a robust portfolio of patents across multiple countries. In addition to its core focus on glaucoma, Smartlens is exploring applications for its technology in monitoring intracranial pressure, associated with neurological disorders and cancers, in collaboration with Stanford University Labs. The company has been recognized for its innovative contributions to medical technology and has gained visibility through various media outlets and industry conferences. Smartlens aims to improve patient outcomes, reduce treatment costs, and mitigate the societal impact of blindness through its cutting-edge solutions.

Novlead Biotech is a developer and manufacturer of medical devices specializing in cardiopulmonary, respiratory, and anti-infection applications. The company leverages technological innovations, particularly the medical application of nitric oxide, to address conditions such as pulmonary hypertension and infectious diseases. By focusing on these critical areas, Novlead Biotech aims to enhance treatment efficiency in hospitals and improve the quality of life for patients. Through its advancements, the company contributes to safer and healthier outcomes in healthcare.

Eaglenos is an IVD company that specialises in medical POCT, home health care devices, and health management systems. It focuses on chemistry, materials, electronics, software, machinery, and biomedical engineering. It helps in the advancement of electrochemistry, microfluidics, signal acquisition, and automation technologies.

Larkspur Biosciences is a biotechnology company dedicated to developing precision immunotherapies aimed at improving cancer treatment outcomes. The company focuses on addressing how tumors manipulate the immune system, creating therapies tailored for specific molecularly defined patient groups. By targeting the critical interactions between tumors and the immune system, Larkspur's approach seeks to enhance patients' immune responses, particularly in colorectal cancer and other malignancies. This strategic focus aims to overcome existing challenges that allow tumors to evade immune detection and attack, thereby advancing the efficacy of cancer therapies.

Xunyuan Technology is a bio-refining and bio-manufacturing platform company based on non-grain carbon sources.

Eluminex Biosciences is focused on researching and commercializing innovative therapies aimed at addressing unmet medical needs in ocular health. Specializing in ophthalmology and tissue regeneration, the company develops solutions based on recombinant human collagen. Its product pipeline is designed to mitigate the effects of aging and overuse on vision, thereby enhancing treatment options for healthcare providers and improving patient outcomes in the diagnosis and management of ocular conditions.

Jushu Biotech is a medical engineering company that focuses on the research and development of synthetic biosensing technology.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Sipeng Technology is an innovative synthetic biology company specializing in the manufacturing of bio-based products. The firm develops advanced synthetic biology technologies, emphasizing the production of negative carbon new materials, polymer monomers, and various high-value compounds. By focusing on sustainable solutions, Sipeng Technology aims to provide clients with eco-friendly alternatives in the bio-based product market, contributing to a more sustainable future.

Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Boston, Massachusetts, founded in 2016. The company focuses on developing innovative treatments for peripheral neuropathies, hemoglobinopathies, and certain oncology indications. Its approach centers on the regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy is advancing the selective HDAC6 inhibitor ricolinostat, which has potential applications in treating sickle cell disease and beta-thalassemia. Through its novel, disease-modifying strategies, Regenacy aims to address significant unmet medical needs in these therapeutic areas.

CytoNiche is engaged in the development of 3D micro-organization engineering technology, primarily for stem cell research. The company utilizes technology derived from Tsinghua University to create innovative solutions such as automated and intelligent stem cell culture amplification processes. Its offerings include high-quality stem cell cultures, injectable 3D micro-tissue treatments, and 3D drug screening microcarriers, which facilitate extensive drug screening operations. CytoNiche aims to provide reliable 3D micro-tissue products and services tailored for research institutes, clinical organizations, stem cell companies, and drug research enterprises, thereby advancing the capabilities in stem cell research and drug development.

Zhengli Technology is a company dedicated to the research, development, production, and sales of advanced invisible orthodontic products, dental restoration items, and specialized dental software systems. It aims to provide comprehensive solutions for dental professionals both in China and internationally. The company’s primary focus is on creating invisible orthodontic appliances that assist patients in enhancing their dental health and straightening their teeth. Through its innovative products and services, Zhengli Technology strives to support dental practitioners in delivering effective care to their patients.

Biosion is a biotech company focused on the development of biologics to treat resistant, relapsed, residual immune, and oncologic diseases.

ITabMed is a clinical-stage biotech company based in Shanghai, China, founded in 2020 as a spin-off from Generon BioMed Ltd. The company specializes in the research and development of immunotherapy drugs aimed at treating cancer. Utilizing its innovative immunotherapy antibody technology platform, ITabMed has developed two products, A-319 and A-337, which have progressed to phase I clinical trials. Additionally, the company is advancing several candidate drug molecules currently in various stages of preclinical development.

Novlead Biotech is a developer and manufacturer of medical devices specializing in cardiopulmonary, respiratory, and anti-infection applications. The company leverages technological innovations, particularly the medical application of nitric oxide, to address conditions such as pulmonary hypertension and infectious diseases. By focusing on these critical areas, Novlead Biotech aims to enhance treatment efficiency in hospitals and improve the quality of life for patients. Through its advancements, the company contributes to safer and healthier outcomes in healthcare.

Neural Galaxy is a brain science company that emerged from Harvard Medical School and the Massachusetts Institute of Technology. The organization focuses on addressing brain disorders through advanced software and hardware technologies. By leveraging breakthrough research in brain science, Neural Galaxy aims to enhance understanding of the brain and high-level intelligence. Its mission includes tackling significant challenges related to brain diseases and improving treatment options, ultimately contributing to a deeper comprehension of human cognition and enhancing overall societal intelligence.

Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.

Cullgen Inc. is a biopharmaceutical company based in San Diego, California, founded in 2018. The company specializes in the development of innovative small molecule therapeutics aimed at treating diseases that currently lack effective therapeutic options, including cancer, inflammatory, and autoimmune diseases. Utilizing its proprietary uSMITE™ platform, Cullgen employs targeted protein degradation technology to selectively degrade disease-causing proteins, even those previously deemed undruggable. This approach enables the creation of first-in-class new chemical entities, providing scientists with novel methodologies for drug discovery and potentially transforming treatment paradigms for difficult-to-treat conditions.

Cardea Bio, Inc. is a biotechnology company based in San Diego, California, focused on developing and commercializing bioelectronics for research and diagnostics. Established in 2013, Cardea utilizes proprietary graphene-based digital biosensors to create advanced biosensor hardware, software, and molecular infrastructure, enabling precision healthcare through improved diagnostic capabilities. The company's product offerings include the AGILE R100, an innovative assay for drug discovery, and the AGILE R200, an automated high-throughput screening solution. Cardea's biosensors convert biomolecular interactions into digital data, allowing for real-time biological signal analysis and access to streaming multi-omics data. Their solutions cater to various applications in life sciences and healthcare, such as small molecule validation, antibody characterization, and biomolecular analysis.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Biocytogen LLC is a biotechnology company based in Worcester, Massachusetts, that specializes in developing gene-targeted animal models for life science research. Founded in 2008, the company offers a range of services, including customized and off-the-shelf mouse models, phenotype analysis, and advanced gene-editing techniques. Its products encompass various types of mice, such as knockin and knockout models, as well as humanized mice, catering to diverse research areas including immunology, neurology, cancer, and infectious diseases. Biocytogen also operates a state-of-the-art animal facility to support its integrated platform for efficient antibody drug discovery and validation. The company collaborates with leading pharmaceutical and biotechnology firms to enhance preclinical research and development processes in the biomedical field.

OncoImmune, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for cancer and autoimmune diseases. The company's portfolio features several key candidates, including CD24Fc, a recombinant fusion protein aimed at preventing acute graft versus host disease in leukemia patients undergoing hematopoietic stem cell transplantation. OncoImmune has completed a Phase II clinical trial for CD24Fc and is preparing to initiate a pivotal trial for this indication. Additionally, the company is developing sialidase inhibitors to prevent sepsis, ONC-392, a monoclonal antibody that minimizes immune-related toxicities while maintaining anti-tumor activity, and Echinomycin, a formulation for treating acute myeloid leukemia. Founded in 2000, OncoImmune is headquartered in Rockville, Maryland.

Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Boston, Massachusetts, founded in 2016. The company focuses on developing innovative treatments for peripheral neuropathies, hemoglobinopathies, and certain oncology indications. Its approach centers on the regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy is advancing the selective HDAC6 inhibitor ricolinostat, which has potential applications in treating sickle cell disease and beta-thalassemia. Through its novel, disease-modifying strategies, Regenacy aims to address significant unmet medical needs in these therapeutic areas.

Apexigen Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, dedicated to the discovery and development of antibody therapeutics for cancer treatment. The company focuses on creating innovative immuno-oncology products that leverage the patient's immune system to effectively combat and eliminate cancer. Apexigen's therapeutic pipeline includes several candidates such as APX005M and APX201 for immuno-oncology, alongside APX003 and TRK-950 for oncology, as well as APX001 for inflammation and APX003 for ocular diseases. Additionally, the company has developed the APXiMAB platform, which facilitates the discovery of antibodies targeting novel immune system components. Founded in 2010, Apexigen aims to advance next-generation therapies that address significant unmet needs in cancer treatment.

Lipidio Pharmaceuticals Inc. is a biopharmaceutical company based in San Diego, California, focused on developing treatments for diseases associated with excess body fat. Founded in 2018, the company's lead drug candidate, GDD3898, targets conditions such as Prader-Willi syndrome, nonalcoholic steatohepatitis (NASH), and weight gain related to antipsychotic medications. Lipidio Pharmaceuticals aims to address significant unmet medical needs in both metabolic disorders and dermatological conditions, including sebaceous hyperplasia and moderate to severe acne. The company's innovative approach seeks to enhance treatment options for healthcare professionals managing these challenging health issues.

Ansun Biopharma, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies to prevent and treat serious human diseases. The company specializes in host-directed anti-viral therapies, which aim to combat respiratory viral infections, including various strains of influenza and parainfluenza viruses. Its lead product candidates include Fludase, designed for the prophylaxis and treatment of respiratory infections, and Viradin, an intravenous therapeutic for sepsis and viral hemorrhagic fevers caused by pathogens such as Ebola and Marburg viruses. Additionally, Ansun Biopharma has developed TOSAP, a formulation technology for drug delivery using microspheres and nanospheres. Founded in 2003, the company was previously known as NexBio, Inc. before rebranding in 2011.

Biocytogen LLC is a biotechnology company based in Worcester, Massachusetts, that specializes in developing gene-targeted animal models for life science research. Founded in 2008, the company offers a range of services, including customized and off-the-shelf mouse models, phenotype analysis, and advanced gene-editing techniques. Its products encompass various types of mice, such as knockin and knockout models, as well as humanized mice, catering to diverse research areas including immunology, neurology, cancer, and infectious diseases. Biocytogen also operates a state-of-the-art animal facility to support its integrated platform for efficient antibody drug discovery and validation. The company collaborates with leading pharmaceutical and biotechnology firms to enhance preclinical research and development processes in the biomedical field.

Doctor Shaoyang operates a medical platform focused on delivering psychological and mental health support services. The company offers a range of services, including health consultations, doctor-patient communication, one-on-one appointment consultations, and pre-diagnosis. This platform facilitates seamless online communication between patients and doctors while ensuring the protection of sensitive information. By prioritizing accessibility and privacy, Doctor Shaoyang aims to enhance the overall experience for users seeking mental health support.

Medtrum is a company focused on simplifying diabetes management through the development and marketing of medical devices and related software. Their products are designed to help patients with various types of diabetes monitor and manage their glucose levels and insulin pump status effectively. Additionally, Medtrum aims to enhance the convenience of healthcare for professionals while exploring advancements in artificial pancreas research.

Cytek Biosciences, Inc. is a manufacturer and supplier of flow cytometry tools and equipment, primarily serving cancer and cell biology research. The company offers a range of products including the Cytek Aurora and Cytek Northern Lights flow cytometers, the DxP Athena flow cytometry system that utilizes advanced technology to resolve dim populations in a multicolor format, and the QbSure quality control program for assessing cytometer performance. Additionally, Cytek provides proprietary cFluor reagents designed to optimize instrument performance in multicolor applications. Established in 1990 and headquartered in Fremont, California, Cytek has expanded its presence with locations in Bethesda, Maryland; Amsterdam, the Netherlands; Tokyo, Japan; and Shanghai, China. The company, formerly known as Cytoville, Inc., rebranded to Cytek Biosciences, Inc. in August 2015.

Profusa, Inc. is a digital health technology company based in Emeryville, California, specializing in the development of tissue-integrated sensors and biosensors aimed at enhancing diabetes management and chronic disease care. Founded in 2009, Profusa focuses on creating biointegrated sensors that allow individuals to monitor their unique body chemistry in real time, thereby transforming personal health management. The company's technology is designed to be user-friendly and cost-effective, providing actionable, clinical-grade data to improve health outcomes. Profusa also develops software that offers biofeedback for chronic disease management and promotes healthy living. Its flagship product, Lumee Oxygen, represents a significant advancement in continuous health monitoring within the European market.

Apexigen Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, dedicated to the discovery and development of antibody therapeutics for cancer treatment. The company focuses on creating innovative immuno-oncology products that leverage the patient's immune system to effectively combat and eliminate cancer. Apexigen's therapeutic pipeline includes several candidates such as APX005M and APX201 for immuno-oncology, alongside APX003 and TRK-950 for oncology, as well as APX001 for inflammation and APX003 for ocular diseases. Additionally, the company has developed the APXiMAB platform, which facilitates the discovery of antibodies targeting novel immune system components. Founded in 2010, Apexigen aims to advance next-generation therapies that address significant unmet needs in cancer treatment.

Ansun Biopharma, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies to prevent and treat serious human diseases. The company specializes in host-directed anti-viral therapies, which aim to combat respiratory viral infections, including various strains of influenza and parainfluenza viruses. Its lead product candidates include Fludase, designed for the prophylaxis and treatment of respiratory infections, and Viradin, an intravenous therapeutic for sepsis and viral hemorrhagic fevers caused by pathogens such as Ebola and Marburg viruses. Additionally, Ansun Biopharma has developed TOSAP, a formulation technology for drug delivery using microspheres and nanospheres. Founded in 2003, the company was previously known as NexBio, Inc. before rebranding in 2011.

Refuge Biotechnologies, Inc. is a Menlo Park, California-based company focused on developing cancer immunotherapies through the application of synthetic biology and gene-editing technology, specifically CRISPR-dCas. Founded in 2015, Refuge aims to enhance cell therapies by creating innovative treatments that can sense their environment and modulate multiple genes simultaneously. This approach allows for more potent and targeted cancer therapies, moving beyond traditional single-target treatments. The company's research and development efforts are centered on advancing both cancer diagnostics and immunotherapies to improve patient outcomes in cancer care.

Biocytogen LLC is a biotechnology company based in Worcester, Massachusetts, that specializes in developing gene-targeted animal models for life science research. Founded in 2008, the company offers a range of services, including customized and off-the-shelf mouse models, phenotype analysis, and advanced gene-editing techniques. Its products encompass various types of mice, such as knockin and knockout models, as well as humanized mice, catering to diverse research areas including immunology, neurology, cancer, and infectious diseases. Biocytogen also operates a state-of-the-art animal facility to support its integrated platform for efficient antibody drug discovery and validation. The company collaborates with leading pharmaceutical and biotechnology firms to enhance preclinical research and development processes in the biomedical field.

Eucure Biopharma is a biotechnology company based in Beijing, China, specializing in the discovery and development of innovative immuno-oncology targeted antibodies. The company's primary focus is on immune checkpoints, with several products having advanced to the Chemistry, Manufacturing, and Controls (CMC) stage and clinical trials initiated in 2019. Eucure Biopharma aims to create antibody treatments that enhance the survival rates of patients with tumors, offering healthcare professionals more effective options for cancer treatment through the development of checkpoint and cancer growth inhibitors.

Shanghai Ligatech Bioscience Co., Ltd. is a company based in Qingpu, China, founded in 2014, dedicated to the design, research and development, production, and sales of medical devices specifically for orthopedic sports medicine. The company develops a variety of products, including molecular weight polyethylene sutures and striped titanium plates, as well as artificial ligaments and fixation systems. In addition to its product offerings, Ligatech Bioscience provides technical advice and services to users, aiming to deliver comprehensive medical solutions tailored for sports professionals. The company emphasizes innovation in its development of biomedical materials and equipment, including imaging systems powered by artificial intelligence and various active devices and implants.

EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.

OncoImmune, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for cancer and autoimmune diseases. The company's portfolio features several key candidates, including CD24Fc, a recombinant fusion protein aimed at preventing acute graft versus host disease in leukemia patients undergoing hematopoietic stem cell transplantation. OncoImmune has completed a Phase II clinical trial for CD24Fc and is preparing to initiate a pivotal trial for this indication. Additionally, the company is developing sialidase inhibitors to prevent sepsis, ONC-392, a monoclonal antibody that minimizes immune-related toxicities while maintaining anti-tumor activity, and Echinomycin, a formulation for treating acute myeloid leukemia. Founded in 2000, OncoImmune is headquartered in Rockville, Maryland.

MicuRx Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing antibiotics to address drug-resistant bacterial infections. Founded in 2007 and headquartered in Palo Alto, California, the company has established a hybrid business model that leverages U.S. research and development alongside cost-effective scientific resources in China. MicuRx's product lineup includes MRX-I, an oral antibiotic targeting multi-drug resistant gram-positive pathogens, and its intravenous prodrug form, MRX-IV. Additionally, the company offers MRX-V, an injectable antibiotic for gram-negative bacteria, and MRX-VIII, a polymyxin for gram-negative infections. The company is also working on a pipeline of antibacterial drugs aimed at combating both gram-positive and gram-negative bacterial pathogens. MicuRx's subsidiary, Shanghai MicuRx, is responsible for commercializing its agents in China while global clinical studies continue.

Refuge Biotechnologies, Inc. is a Menlo Park, California-based company focused on developing cancer immunotherapies through the application of synthetic biology and gene-editing technology, specifically CRISPR-dCas. Founded in 2015, Refuge aims to enhance cell therapies by creating innovative treatments that can sense their environment and modulate multiple genes simultaneously. This approach allows for more potent and targeted cancer therapies, moving beyond traditional single-target treatments. The company's research and development efforts are centered on advancing both cancer diagnostics and immunotherapies to improve patient outcomes in cancer care.

Profusa, Inc. is a digital health technology company based in Emeryville, California, specializing in the development of tissue-integrated sensors and biosensors aimed at enhancing diabetes management and chronic disease care. Founded in 2009, Profusa focuses on creating biointegrated sensors that allow individuals to monitor their unique body chemistry in real time, thereby transforming personal health management. The company's technology is designed to be user-friendly and cost-effective, providing actionable, clinical-grade data to improve health outcomes. Profusa also develops software that offers biofeedback for chronic disease management and promotes healthy living. Its flagship product, Lumee Oxygen, represents a significant advancement in continuous health monitoring within the European market.